EURURO Vol. 71 No. 4

626 692

13. Conclusions
The present text represents a summary of the 2016 EAU[13_TD$DIFF]-
ESTRO-SIOG PCa [8_TD$DIFF]Guidelines. For more detailed information
and a full list of references, refer to the full-text version
(ISBN 978-90-79754-71-7), available at the EAU Web site
Author contributions: Nicolas Mottet had full access to all the data in the
study and takes responsibility for the integrity of the data and the
accuracy of the data analysis.
Study concept and design: Mottet, Cornford.
Acquisition of data: Mottet, Bolla, De Santis, Henry, Joniau, Lam, Mason,
Matveev, Moldovan, van den Bergh, Van den Broeck, van der Poel, van
der Kwast, Rouvie`re, Wiegel, Cornford.
Analysis and interpretation of data: Mottet, Bolla, Briers, De Santis, Henry,
Joniau, Lam, Mason, Matveev, Moldovan, van den Bergh, van der Poel,
van der Kwast, Rouvie`re, Wiegel, Cornford.
Drafting of the manuscript: Mottet.
Critical revision of the manuscript for important intellectual content:
Mottet, Bellmunt, Bolla, Briers, Cumberbatch, De Santis, Fossati, Gross,
Henry, Joniau, Lam, Mason, Matveev, Moldovan, van den Bergh, Van den
Broeck, van der Poel, van der Kwast, Rouvie`re, Schoots, Wiegel, Cornford.
Statistical analysis: None.
Obtaining funding: None.
Administrative, technical, or material support: None.
Supervision: Mottet.
Other (specify): None.
Financial disclosures: Nicolas Mottet certifies that all conflicts of interest,
including specific financial interests and relationships and affiliations
relevant to the subject matter or materials discussed in the manuscript
(eg, employment/ affiliation, grants or funding, consultancies, honoraria,
stock ownership or options, expert testimony, royalties, or patents filed,
received, or pending), are the following: Nicolas Mottet receives grants/
research support from Takeda Pharmaceutical, Millennium, Astellas,
Pierre Fabre, Sanofi, and Pasteur. He receives honoraria or consultation
fees from Takeda Pharmaceutical, Millennium, [14_TD$DIFF]Janssen, Astellas, BMS,
Bayer, Ipsen, Ferring, Novartis, Nucle´tron, Pierre Fabre, Sanofi, and
Zeneca. Joaquim Bellmunt is a company consultant for Janssen, Astellas,
Pierre Fabre, Genentech, Merck, Ipsen, Pfizer, Novartis and Sanofi
Aventis. He has received research support from Takeda, Novartis and
Sanofi and received travel grants from Pfizer and Pierre Fabre. Michel
Bolla receives company honoraria from Ipsen and Astra Zeneca, is a
company consultant for Janssen, and receives travel grants from Janssen,
AstraZeneca, and Astellas. Erik Briers is a liaison officer for the European
Prostate Cancer Coalition, a member of the ethics committee/ patient
advisory group for REQUITE (Validating predictive models and
biomarkers of radiotherapy toxicity to reduce side effects and improve
quality of life in cancer survivors), member of ESR-PAG (patient advisory
group on medical imaging), member of the Skeletal Care Academy, and
member of the European Medicines Agency’s Patients’ and Consumers’
Working Party. Maria De Santis is a company consultant for Glaxo Smith
Kline, Janssen, Bayer, Novartis, Pierre Fabre, Astellas, Amgen, Eisai Inc.,
ESSA, Merck, and Synthon. She receives company speaker honoraria
from Pfizer, Takeda, Sanofi Aventis, Shionogi, Celgene, and Teva
OncoGenex, participates in trials for Pierre Fabre, Astellas, and Roche,
and receives fellowships and travel grants from Bayer, Novartis, Ferring,
Astellas, Sanofi Aventis, and Janssen. She receives grants/research
support from Pierre Fabre and honoraria from AstraZeneca, participates
in trials for Exelixis, Bayer, and Roche, and is a company consultant for
Synthon. Steven Joniau is a company consultant for Astellas, Ipsen, Bayer,
Sanofi, and Janssen. He receives company honoraria from Astellas,
Amgen, Bayer, Sanofi, Janssen, and Ipsen, participates in trials for
Astellas, Bayer, and Janssen, receives fellowships and travel grants from
Astellas, Amgen, Bayer, Sanofi, Janssen, Ipsen, and Pfizer. Thomas B. Lam
is a company consultant for Pfizer, GSK, Astellas, and Ipsen, receives
company speaker honoraria from Pfizer, GSK, Astellas, and Ipsen.
Malcolm D. Mason is a company consultant for Bristol-Myers Squibb,
Janssen, Bayer, Sanofi, and Dendreon, and he receives company speaker
honoraria from Takeda and Bayer. Seva Matveev participates in trials for
Astellas, Pfizer, and Novartis, and receives company speaker honoraria
from Sanofi and Astellas. Henk G. van der Poel is a company consultant
for Intuitive Surgical and participates in trials for Astellas and Steba
Biotech. He receives grants/research support from Astellas. Olivier
Rouvie`re is a company consultant for EDAP-TMS, Bracco, and Philips. He
receives company speaker honoraria from EDAP-TMS and Bracco and
participates in trials for EDAP-TMS and Bracco. Thomas Wiegel receives
company speaker honoraria from Astellas, Takeda, Hexal, Ipsen, Janssen-
Cilac, and Ferring. Philip Cornford is a company consultant for Astellas,
Ipsen and Ferring. He receives company speaker honoraria from Astellas,
[14_TD$DIFF]Janssen, Ipsen and Pfizer and participates in trials from Ferring, and
receives fellowships and travel grants from Astellas and [14_TD$DIFF]Janssen. Marcus
G. Cumberbatch, Nicola Fossati, Tobias Gross, Ann M. Henry, Paul L.
Moldovan, Ivo G. Schoots, Roderick C.N. van den Bergh, Thomas Van den
Broeck, and Theo van der Kwast have nothing to disclose.
Funding/Support and role of the sponsor: None.
References
[1]
.
[2] Oxford Centre for Evidence-Based Medicine – levels of evidence
(March 2009). Centre for Evidence-Based Medicine Web site.
[3]
[4]
[5]
.
[6]
[7]
.
[8]
[9]
[10]
[11]
E U R O P E A N U R O L O G Y 7 1 ( 2 0 1 7 ) 6 1 8 – 6 2 9 626